FKBP12 Protein - ACROBiosystems

Home
Product & Service

Products by Category

Recombinant proteins and more
Multi-pass Transmembrane Proteins and Technology PlatformsNew FDA DMF Filed ProteinsHot SARS-CoV-2 Related ProductsHot Immune Checkpoint ProteinsHot Targets of CAR-T Cell TherapyNew CytokinesHot Biosimilar Drug TargetsHot Tumor MicroenvironmentHot Anti-idiotypic AntibodyHot Fc Receptor Proteins Llama IgG Fc Fusion ProteinNew Bio-Markers & CD Antigens ActiveMax -Best Cytokines Viral Proteins Enzymes Antibodies All Recombinant Proteins
Services

Innovation Lab ServicesNew SPR /BLI analytical serviceNew

Pre-labeled proteins
Biotinylated protein collectionHot FITC & PE labeled ProteinsNew Fluorescent fusion proteins
Kits
SARS-CoV-2 Related Kit ProductsNew Pre-Coupling Magnetic BeadsNew Universal ELISA Kits ELISA Assay Kits for Quantitative Analysis of Therapeutic Antibodies in Serum Samples Inhibitor Screening Kits
Others
HPLC-verified Proteins Integrin - Integrin Proteins BCMA - B-Cell Maturation Antigen TIGIT - TIGIT Signaling Axis CD24 & Siglec-10 proteinsHot

Hot Products

Supports on COVID-19 R&D
Reagents for vaccine developmentNew Reagents for diagnostic developmentNew SARS-CoV-2 related productsNew SARS-CoV-2 related kitsNew SARS-CoV-2 mutant productsNew
Others
Multi-pass Transmembrane Proteins and Technology PlatformsNew Bispecific antibody targetsHot Targets for ADCsHot IL-2 ReceptorsHot CD19 proteinsHot Anti-FMC63 mAbHot CD3 proteinsHot B7 family proteinsHot TNFSF proteinsHot VEGF proteinsHot CD39/CD73 proteinsNew Siglec-15 proteinsHot CD20 proteinsExclusive PD1 proteinsHot
Support

How to Order Shipping & Payments Global Distributors Testimonials Download Brochures Download COA
Application

The Process of How SARS-CoV-2 Infects the Host Quantitative Analysis of mAb in Serum Evaluation of CAR Expression
X-LAB
Company

About Us Join Us Contact Us
Activities

News Exhibitions Promotion
COVID-19 R&D ^New

FKBP12

Brief Information

Name:FK506-binding protein 1A
Target Synonym:Peptidyl-Prolyl Cis-Trans Isomerase FKBP1A,FK506-Binding Protein, T-Cell, 12-KD,FK506-Binding Protein 1A (12kD),Protein Kinase C Inhibitor 2,FK506-Binding Protein 12,FK506 Binding Protein12,FK506-Binding Protein 1,FKBP12-Exip3,Calstabin 1,PPIASE,PKC12,PKC

Number of Launched Drugs:1
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Approved


FKA-H5122	Human	Human FKBP12 / FKBP1A Protein, His Tag

Cat. No.

Species

Product Description

Structure

Purity

Feature

FKA-H5122

Human

Human FKBP12 / FKBP1A Protein, His Tag

Synonym Name

FKBP1A,FKBP1,Calstabin-1,FKBP12,Rotamase,PKC12,PPIASE

Background

Peptidyl-prolyl cis-trans isomerase FKBP1A, a member of the FKBP-type PPIase family and FKBP1 subfamily, is also known as FK506-binding protein 1A, immunophilin FKBP12 and 12 kDa FK506-binding protein, which contains one PPIase FKBP-type domain. FKBP1A is a cis-trans prolyl isomerase that binds the immunosuppressants FK506 (tacrolimus) and rapamycin (sirolimus).FKBP1A interacts with several intracellular signal transduction proteins including type I TGF-beta receptor. FKBP1A can also interact with multiple intracellular calcium release channels including the tetrameric skeletal muscle ryanodine receptor. Furthermore, FKBP1A can recruite SMAD7 to ACVR1B which prevents the association of SMAD2 and SMAD3 with the activin receptor complex, thereby blocking the activin signal.

Clinical and Translational Updates

Public Drug Information

Name	Research Code	Research Phase	Company	First Brand Name	First Approved Country	First Indication	First Approved Company	First Approved Date	Indications	Clinical Trials
Tacrolimus Hydrate	L-679934; FK-506MR; FK-506E; FK-506; MR-4; RTU-007; FR-900506; LCP-Tacro	Approved	Astellas Pharma Inc	Protopy, Graceptor (as hydrate), Advagraf, Envarsus, Modigraf, Astagraf XL, Protopic, TacroBell, Prograf (as hydrate), Hecoria (as hydrate), Hexal, Envarsus XR, Talymus	EU	Dermatitis, Atopic	s:14:"Leo Pharma A/S";	1993-01-01	Arthritis, Rheumatoid; Dermatitis, Atopic; Coronary Restenosis; Keratoconjunctivitis; Rejection in heart transplantation; Colitis, Ulcerative; Asthma; Conjunctivitis, Allergic; Psoriasis; Conjunctivitis; Lupus Nephritis; Rejection of organ transplantation; Rejection of renal transplantation; Graft vs Host Disease; Rejection of lung transplantation; Cystitis; Keratoplasty rejection; Glomerulonephritis, IGA; Renal Insufficiency; Rejection of liver transplantation; Liver Failure; Myasthenia Gravis; Bone marrow transplant rejection	Details

Clinical Drug Information

Name	Research Code	Research Phase	Company	Indications	Clinical Trials
Rimiducid	AP-1903	Phase 2 Clinical	Ariad Pharmaceuticals Inc	Prostatic Neoplasms; Congenital Bone Marrow Failure Syndromes; Anemia, Sickle Cell; Lymphohistiocytosis, Hemophagocytic; Carcinoma, Pancreatic Ductal; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Myeloid, Acute; Urogenital Neoplasms; Metabolic Diseases; Osteopetrosis; Anemia, Aplastic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Immunodeficiency Diseases; Uveal melanoma; Multiple Myeloma; Prostatic Neoplasms, Castration-Resistant; Pancreatic Neoplasms; Fanconi Anemia; Anemia, Diamond-Blackfan; Hemoglobinopathies; Myelodysplastic Syndromes; Thalassemia; Genital Neoplasms, Male; Hematologic Neoplasms; Leukemia	Details